Received Apr 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
redness and swelling at the injection site; redness and swelling at the injection site; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of injection site erythema in a patient who received Herpes zoster (Shingrix) for prophylaxis. On 11-APR-2025, the patient received Shingrix. In APR-2025, an unknown time after receiving Shingrix, the patient experienced injection site erythema (Verbatim: redness and swelling at the injection site) and injection site swelling (Verbatim: redness and swelling at the injection site). The outcome of the injection site erythema was not reported and the outcome of the injection site swelling was not resolved. It was unknown if the reporter considered the injection site erythema and injection site swelling to be related to Shingrix. It was unknown if the company considered the injection site erythema and injection site swelling to be related to Shingrix. Additional Information: GSK Receipt Date : 12-APR-2025 This case was reported by a patient via interactive digital media. The patient got the vaccine the day before reporting and had redness and swelling at the injection site. The reporter asked if he/she could take Motrin or Benadryl to help with the swelling.; Sender's Comments: US-GSK-US2025AMR046242:same reporter US-GSK-US2025AMR046252:same reporter US-GSK-US2025AMR046239:same reporter US-GSK-US2025AMR046250:same reporter US-GSK-US2025AMR046237:same reporter